Key result
Bisphosphonate therapy prolonged the median time to the first skeletal-related event compared to no bisphosphonates in patients with soft tissue sarcoma.
Why the study?
Do bisphosphonates delay skeletal related events in patients with soft tissue sarcoma and bone metastases?
Observational (n=135)
Yes
Do bisphosphonates delay skeletal related events in patients with soft tissue sarcoma and bone metastases?
In patients with soft tissue sarcoma and bone metastases, bisphosphonates significantly delay the onset of skeletal-related events.
Answers are grounded in this paper and cite their sources.
May support bisphosphonate use to delay skeletal events in soft tissue sarcoma; hypothesis-generating and requires randomized confirmation.
BACKGROUND: We surveyed the natural history of bone metastases in patients affected by soft tissue sarcoma (STS). METHODS: This multicenter retrospective observational study included 135 patients. Histological subtype, characteristics of bone metastases, treatment, skeletal related events (SREs) and disease outcome were recorded. RESULTS: The most represented histological subtypes were leiomyosarcoma (27%) angiosarcoma (13%) and undifferentiated sarcoma (8%). Axial skeleton was the most common site for bone involvement (70%). In 27% of cases, bone metastases were present at the time of diagnosis. Fifty-four (40%) patients developed SREs and the median time to first SRE was 4 months (range 1-9). The most common SRE was the need for radiotherapy (28%) followed by pathological fracture (22%). Median survival after bone progression was 6 months (range 1-14). SREs were associated with decreased overall survival (OS) (P = 0.04). A subgroup analysis revealed that bisphosphonates significantly prolonged median time to first SRE (5 versus 2 months; P = 0.002) while they did not determine an improvement in OS, although a favourable trend was identified (median: 7 versus 5 months; P = 0.105). CONCLUSIONS: This study illustrates the burden of bone disease from STS and supports the use of bisphosphonates in this setting.
No takes yet. Share an insight, caveat, or question.
Vincenzi et al. (2013) conducted an observational in Soft tissue sarcoma with bone metastases (n=135). Bisphosphonates vs. No bisphosphonates was evaluated on Median time to first skeletal-related event (SRE) in months (p=0.002). Bisphosphonate therapy prolonged the median time to the first skeletal-related event compared to no bisphosphonates in patients with soft tissue sarcoma.
Synapse has enriched 10 related papers. Consider them for comparative context: